TOOKAD®Soluble vascular‐targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer
Top Cited Papers
Open Access
- 5 June 2013
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 112 (6), 766-774
- https://doi.org/10.1111/bju.12265
Abstract
Objectives To evaluate the optimal treatment conditions and effects of TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy in patients with localised prostate cancer. To evaluate the safety and quality of life after TOOKAD® Soluble VTP treatment in patients with localised prostate cancer. Patients and Methods Men (aged >18 years) diagnosed with localised prostate cancer, who were suitable for active surveillance, were invited to take part in the study. Patients who had received prior or current treatment for their cancer were excluded. There were two parts to the study: in part one, patients were assigned to one of two treatment groups based on the size of their prostates (patients with prostate size ® Soluble and patients with prostate size ≥60 mL would receive 6 mg/kg TOOKAD® Soluble both activated with 200 J/cm light). In part two, patients were assigned to one of two treatment groups based on predefined criteria and received either 4 or 6 mg/kg TOOKAD® Soluble and 200 or 300 J/cm light. VTP was conducted under general anaesthesia using TOOKAD® Soluble administered intravenously and activated by light‐diffusing fibres within the prostate via the perineum. Follow‐up was conducted for 6 months. Magnetic resonance imaging (MRI) carried out at 1 week after VTP and transrectal prostate biopsy at 6 months were the key endpoints. Adverse event (AE) recording and patient‐reported outcome measures were collected. Results In all, 86 patients were enrolled in the study and 85 patients received treatment. Of the 85 treated patients, one patient discontinued (due to withdrawal of consent). At 6 months, 61/83 (74%) patients who underwent prostate biopsy had histopathology that was negative for prostate cancer (95% confidence interval (CI) 62.7–82.6%). Considering patients who received 4 mg/kg TOOKAD® Soluble and 200 J/cm light (unilateral), which are considered optimal treatment parameters, 38/46 (83%) patients had histopathology from the biopsies that was negative for prostate cancer at 6 months (95% CI 68.6–92.2%; P < 0.001). The mean percentage of necrosis of the targeted prostate tissue at 7 days after VTP was 78% overall (83 patients) with extraprostatic necrosis reported in 76% (63/83) of patients. Considering patients who received 4 mg/kg TOOKAD® Soluble and 200 J/cm light (unilateral), the mean 7‐day necrosis percentage was 88% (46 patients) with extraprostatic necrosis reported in 72% (33/46) of patients. All occurrences of extraprostatic necrosis were considered clinically acceptable and none were associated with any clinical sequelae. The mean percentage prostate necrosis at 7 days was statistically significantly higher (P < 0.001) in patients treated with a therapeutic light density index (LDI) of ≥1 than those treated with a LDI of ® Soluble and 200 J/cm light are the optimal treatment conditions for the VTP procedure resulting in >80% of patients treated with this regimen having a negative biopsy at 6 months. Overall, the treatment was well tolerated and exhibited early signs of efficacy for minimally invasive focal treatment of localised prostate cancer.Keywords
This publication has 20 references indexed in Scilit:
- Radical Prostatectomy versus Observation for Localized Prostate CancerThe New England Journal of Medicine, 2012
- Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyThe Lancet Oncology, 2012
- Focal Therapy in the Management of Prostate Cancer: An Emerging Approach for Localized Prostate CancerAdvances in Urology, 2012
- A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11Physics in Medicine & Biology, 2011
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with TookadPLOS ONE, 2010
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, 2007
- Novel Water-soluble Bacteriochlorophyll Derivatives for Vascular-targeted Photodynamic Therapy: Synthesis, Solubility, Phototoxicity and the Effect of Serum Proteins¶Photochemistry and Photobiology, 2007
- WST11, A Novel Water-soluble Bacteriochlorophyll Derivative; Cellular Uptake, Pharmacokinetics, Biodistribution and Vascular-targeted Photodynamic Activity Using Melanoma Tumors as a Model¶Photochemistry and Photobiology, 2005